The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. by Lip, GYH et al.
  	

The Relationship of Renal Function to Outcome: A Post hoc Analysis from
the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of
Atrial Fibrillation (ENSURE-AF) study
GYH Lip, N Al-Saady, MD Ezekowitz, M Banach, A Goette
PII: S0002-8703(17)30209-0
DOI: doi: 10.1016/j.ahj.2017.07.010
Reference: YMHJ 5485
To appear in: American Heart Journal
Received date: 27 March 2017
Accepted date: 16 July 2017
Please cite this article as: Lip GYH, Al-Saady N, Ezekowitz MD, Banach M, Goette
A, The Relationship of Renal Function to Outcome: A Post hoc Analysis from the
EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation
(ENSURE-AF) study, American Heart Journal (2017), doi: 10.1016/j.ahj.2017.07.010
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 1 
The Relationship of Renal Function to Outcome: A Post hoc Analysis from the 
EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial 
Fibrillation (ENSURE-AF) study 
RCT# NCT02072434 
Lip GYH,1 Al-Saady N,2 Ezekowitz MD,3 Banach M,4 Goette A5 
1. University of Birmingham Institute of Cardiovascular Sciences, City Hospital, 
Birmingham, B18 7QH, United Kingdom; Aalborg Thrombosis Research Unit, 
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.  
2. Sr. Medical Director, Cardiovascular/Metabolic, Covance Inc., Osprey House, 
Maidenhead Park Office, Westacott Way, Littlewick Green, Maidenshead, SL6 3QH, 
United Kingdom.  
3. Department of Cardiovascular Medicine, Sidney Kimmel Jefferson Medical College at 
Thomas Jefferson University and Lankenau Medical Center, 1999 Sproul Road, Suite 
26, Broomall, Pennsylvania, 19008 United States.  
4. Head, Department of Hypertension, Chair of Nephrology and Hypertension, MUL, 
Lodz, Poland. 
5. Chief of Cardiology and Intensive Care Medicine, St. Vincenz-Hospital, Paderborn, 
Am Busdorf 2, Paderborn, Nordrhein-Westfalen, 33098, Germany and Working 
Group: Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg, 
Germany.  
 
Correspondence to: 
Professor Gregory Y H Lip, MD, FRCP, DFM, FACC, FESC 
University of Birmingham 
Institute of Cardiovascular Sciences 
City Hospital 
Birmingham, B18 7QH 
United Kingdom 
Phone: +44 121 507 5080  
Fax: +44 121 554 4083 
Email: g.y.h.lip@bham.ac.uk 
 
Abstract Word Count: 345 
Word Count:  1834 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 2 
Abstract 
Background: The ENSURE-AF study (NCT 02072434) of anticoagulation for 
electrical cardioversion in non-valvular atrial fibrillation (NVAF) showed comparable 
low rates of bleeding and thromboembolism between the edoxaban and the 
enoxaparin–warfarin treatment arms. This post hoc analysis investigated the 
relationship between renal function and clinical outcomes. 
Methods: ENSURE-AF was a multicenter, PROBE evaluation trial of edoxaban 60 
mg, or dose reduced to 30 mg/day for weight ≤60 kg, CrCl (creatinine clearance; 
Cockroft-Gault) ≤50 ml/min, or concomitant P-glycoprotein [P-gp] inhibitors) 
compared with therapeutically monitored enoxaparin–warfarin in 2,199 NVAF 
patients undergoing electrical cardioversion. Efficacy and safety outcomes and time 
in therapeutic range (TiTR) in the warfarin arm were analyzed in relation to CrCl in 
prespecified ranges ≥15 and ≤30; >30 and ≤50; >50 and <80 and ≥80 ml/min, and an 
exploratory ≥95 ml/min analysis.  
Results: 1,095 subjects were randomized to edoxaban and 1,104 to enoxaparin–
warfarin. Mean age was 64.3±10 and 64.2±11 years. Mean TiTR was progressively 
lower with reducing CrCl strata, being 66.8% in those with CrCl >30 to ≤50, 
compared to 71.8% in those with CrCl ≥80. The Odds Ratios for the primary efficacy 
and safety endpoints were comparable for the different predefined renal function 
strata; given the small numbers the 95% CI included 1.0. In the subset of those with 
CrCl ≥95, the Odds Ratios showed consistency with the other CrCl strata. When CrCl 
was assessed as a continuous variable, there was a non-significant trend towards 
higher major or clinically relevant non-major bleeding with reducing CrCl levels, with 
no significant differences between the 2 treatment arms. When we assessed CrCl at 
baseline compared to end of treatment, there were no significant differences in CrCl 
change between the edoxaban and enoxaparin–warfarin arms. The proportions with 
worsening of renal function (defined as a decrease of >20% from baseline) were 
similar in the 2 treatment arms. 
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Conclusion: Given the small number of events in ENSURE-AF, no effect of renal 
(dys)function was demonstrated in comparing edoxaban to enoxaparin–warfarin for 
cardioversion; efficacy and safety of edoxaban remained consistent even in patients 
with normal or supranormal renal function. 
 
Key words: cardioversion, oral anticoagulant, renal function, stroke, 
thromboembolism  
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Introduction  
The availability of the nonvitamin K antagonist oral anticoagulants (NOACs) has 
transformed the landscape for the prevention of atrial fibrillation (AF)-related stroke. 
Nonetheless, all of the NOACs have a degree of renal excretion, ranging from the 
highest being for dabigatran (80% renal excreted) to 50% for edoxaban to 33% for 
rivaroxaban and 27% for apixaban.1 In contrast, warfarin is eliminated principally 
through hepatic metabolism and is not directly renally excreted.2 
Patients with AF and impaired renal function are at high risk of stroke, 
thromboembolism, myocardial infarction, death and serious bleeding.3 In patients 
with supranormal renal function, with eGFR >95ml/min some concern has been 
expressed for less efficacy in ischemic stroke prevention, seen in a post hoc 
subgroup exploratory analyses for edoxaban by the United States FDA.4,5 
The ENSURE-AF study (ClinicalTrials.gov Identifier: NCT02072434) of 
anticoagulation for electrical cardioversion in non-valvular atrial fibrillation (NVAF) 
showed comparable low rates of bleeding and thromboembolism between the 
edoxaban and the enoxaparin–warfarin treatment arms.6 In this post hoc analysis 
from ENSURE-AF we investigated the relationship between renal function and 
blinded adjudicated outcomes. 
 
Methods 
ENSURE-AF was a multicenter, PROBE evaluation trial of edoxaban 60 mg once 
daily or dose adjusted 30 mg/day if weight ≤60 kg, CrCl (creatinine clearance) ≤50 
ml/min, and/or concomitant use of P-glycoprotein (P-gp) inhibitors compared with 
therapeutically monitored enoxaparin–warfarin in 2,199 patients with NVAF of at 
least 48 hours and no longer than 12 months undergoing electrical cardioversion.7  
 By protocol and as published previously,6,7 patients were stratified according 
to cardioversion approach (TEE or non-TEE) as determined by the local investigator. 
In the TEE-guided stratum, both the TEE and cardioversion had to be performed 
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within three days of randomization. Patients in the warfarin arm with INR <2 started 
treatment with a minimum of one dose each of enoxaparin and warfarin before 
cardioversion and these drugs were continued until INR ≥2 was obtained. After a 
therapeutic range was achieved, patients were to discontinue enoxaparin and 
continue warfarin until end of treatment (day 28 following the procedure). Patients 
randomized to the edoxaban arm had to start treatment at least two hours prior to 
electrical cardioversion. The next dose of edoxaban was taken the day after 
cardioversion and then continued on a 24-hour cycle until day 28 post cardioversion. 
Patients with thrombi on TEE had a choice of completing 28 days of study treatment 
without cardioversion or being discontinued from the study. All patients were followed 
up for safety for another 30 days after completing or discontinuing the treatment. 
In all patients in the non-TEE-guided stratum, electrical cardioversion was 
performed at a minimum of 21 days following the start of treatment. Patients in the 
enoxaparin–warfarin arm received anticoagulation for a minimum of 21 days from the 
day of randomization. Patients with an INR <2 at randomization received enoxaparin 
and daily warfarin until the INR was ≥2·0. At that time, enoxaparin was discontinued 
and warfarin continued for the duration of the study. In the edoxaban arm, patients 
received edoxaban for a minimum of 21 days before cardioversion followed by the 
procedure and an additional 28 days of treatment. All patients in the non-TEE guided 
strategy were followed for safety for 30 days after completing treatment.  
Patients were also stratified according to prior experience in taking 
anticoagulants at the time of randomization (i.e. anticoagulant-experienced or 
anticoagulant-naïve); and selected edoxaban dose (60 mg QD or reduced 30 mg QD 
dose). 
Briefly, categorical evaluation based on renal function was assessed at baseline 
and at the end of treatment, as per the clinical trial protocol. The central laboratory 
(Quintiles Q2 Solutions) evaluated the CrCl based on Cockcroft-Gault formula to 
determine renal function. Estimation of CrCl for males: = (140 – age [years]) x (body 
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weight [kg]) / (72 x serum creatinine [mg/dL]); estimation for females = CrCl = 0.85 x 
(140 – age [years]) x (body weight [kg]) / (72 x serum creatinine [mg/dL]. All clinical 
events, both for efficacy and safety were evaluated by a blinded adjudication 
committee composed of cardiologist/hematologist.7 
The primary efficacy analysis was comparing the occurrence of a composite 
endpoint of stroke, systemic embolic event (SEE), myocardial infarction (MI), and 
cardiovascular death (CVD) between the edoxaban group and the enoxaparin–
warfarin group from randomization to end of follow-up and was performed on the 
intention-to-treat population, all individuals who were enrolled into the study and 
randomly assigned.  
The primary safety endpoint of the trial was the composite of major + clinically 
relevant non-major (CRNM) bleeding which occurred during the on treatment period, 
defined as the time period the patient was taking study medication plus up to 3 days 
after the last dose for that time period. Any bleeding was defined as the composite of 
major + CRNM + minor bleeding from time of first administration of study drug to end 
of treatment +3 days. Patients were followed for 28 days on study drug after 
cardioversion plus another 30 days to assess safety on an investigator-prescribed 
standard of care.  
Efficacy and safety outcomes and time in therapeutic range (TiTR) in the 
warfarin arm were analyzed in relation to CrCl in prespecified ranges ≥15 and ≤30; 
>30 and ≤50; >50 and <80 and ≥80 ml/min, and an exploratory ≥95 ml/min analysis). 
The same outcome parameters were also assessed with CrCl as a continuous 
variable. 
  
Statistical methods 
Time in therapeutic range (TiTR) for a patient is defined as the percent of time 
sustained in international normalized ratio (INR) therapeutic range (2.0 ≥ INR ≤ 3.0), 
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from the first date of achieving 2.0 ≥ INR ≤ 3.0 during the on-treatment period. Mean 
TiTR was shown for all renal function strata. Demographic and baseline 
characteristics were summarized by treatment group and renal function stratum. 
Descriptive statistics were presented for the baseline CrCl and the change from 
baseline to end of treatment. The difference of the change from baseline between 
two treatment groups was assessed using an ANOVA model. Frequency and 
percentage of patients with worsening renal function at the end of treatment were 
presented and compared using Chi-square test. The associations of CrCl strata with 
other binary variables and ordinal variables were evaluated by Cochran-Armitage 
trend test and Spearman correlation coefficient, respectively. Breslow-Day-Tarone 
test was performed to assess homogeneity of odds ratio across CrCL strata. 
 
The ENSURE-AF study was sponsored and funded by Daiichi Sankyo Pharma 
Development and Daiichi Sankyo Development, Ltd. No funding was received for the 
present work. The authors are solely responsible for the design and conduct of this 
study, all study analyses, the drafting and editing of the paper and its final contents. 
 
Results 
1,095 subjects were randomized to edoxaban and 1,104 to enoxaparin–warfarin. 
Mean age was 64.3±10 and 64.2±11 years, respectively, and overall mean 
CHA2DS2-VASc score was 2.6. Patient demography and clinical features are 
summarized in Table 1 in relation to CrCl strata. Mean age and the proportion of 
females progressively increased as CrCl decreased (P<0.0001 for both variables). 
The proportions of paroxysmal and persistent AF were fairly similar across all CrCl 
strata. More comorbidities, such as heart failure, were generally more common in 
those with low CrCl (≤50), leading to a higher stroke risk, as reflected by higher mean 
CHA2DS2-VASc score. Higher mean HAS-BLED score was evident in those with CrCl 
≤50. 
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 Efficacy and safety endpoints in relation to renal function strata and treatment 
allocation are shown in Table 2. Mean TiTR was progressively lower with reducing 
CrCl strata, being 66.8% in those with CrCl >30 to ≤50, compared to 71.8% in those 
with CrCl ≥80 although this trend was not statistically significant (P=0.199). 
The Odds Ratios for the primary efficacy and safety endpoints were 
comparable for the different predefined (≥15 to ≤30, >30 to ≤50, >50 to <80, ≥80) 
renal function strata; given the small numbers the 95% CI included 1.0. In the subset 
of those with CrCl ≥95, the Odds Ratios showed consistency with the other CrCl 
strata. 
When CrCl was assessed as a continuous variable, there was a 
nonstatistically significant trend towards higher events in the efficacy analysis 
(composite of stroke, SEE, MI, and CVD) and in the safety analysis (major + CRNM 
bleeding) with reducing CrCl levels (Figure 1 and Figure 2), with no significant 
differences between the 2 treatment arms. 
When we assessed CrCl at baseline compared to end of treatment, there 
were no significant differences in CrCl change between the edoxaban and 
enoxaparin–warfarin arms. The proportions with worsening of renal function (defined 
as a decrease of >20% from baseline) were similar in the 2 treatment arms (Table 3). 
 
Discussion 
In this ancillary analysis from ENSURE-AF, our principal findings are the following: (i) 
as renal function declines, mean age and comorbidities were higher, and mean TiTR 
was progressively lower with reducing CrCl strata; (ii) the Odds Ratios for the primary 
efficacy and safety endpoints were comparable for the different predefined renal 
function strata, with non-significant trends; and (iii) in the subset of those with CrCl 
≥95, the Odds Ratios showed consistency with the other CrCl strata, in relation to 
efficacy versus safety. 
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Patients with AF and renal impairment represent a high risk group of patients, 
with a greater risk of stroke, myocardial infarction, death and serious bleeding3. As 
expected, we noted an increase in age and comorbidities, as well as stroke risk, with 
decreasing CrCl levels. Interestingly we also observed a small trend towards slightly 
less good anticoagulation control (but TiTR was still high, ≥68%) at lower CrCl strata, 
as was seen in other studies showing poorer anticoagulation control with renal 
impairment.8-11 
Nonetheless, the efficacy and safety of edoxaban compared to enoxaparin–
warfarin remained consistent, irrespective of CrCl strata. Even in the subset of those 
with CrCl ≥95, the Odds Ratios showed consistency with the other CrCl strata, with 
no signal for decreased efficacy and/or safety. 
When CrCl was assessed as a continuous variable, there was a non-
significant trend towards higher major or CRNM bleeding with reducing CrCl levels 
(as expected, and consistent with other studies),12 with no significant differences 
between the 2 treatment arms, and the apparent wide confidence intervals, given the 
low event rates. This observation of higher event rates with lower CrCl is generally 
consistent with findings from other Phase 3 NOAC trials, notwithstanding the low 
event rates in these patients.12,13 The higher event rates in patients with low CrCl 
may be associated with other comorbidities and perhaps reduced therapeutic control 
due to increased exposure for renally dependent anti -FXa clearance. 
When we assessed CrCl at baseline compared to end of treatment, we 
observed no significant differences in CrCl change between the edoxaban and 
enoxaparin–warfarin arms. The proportion of patients with worsening renal function 
(defined as a decrease of >20% from baseline) were also similar in the 2 treatment 
arms. In the RE-LY trial, a post hoc analysis showed that renal function decline was 
worse on warfarin compared to dabigatran14; however, our smaller sample size and 
shorter follow-up in the present study precludes similar conclusions. 
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Limitations 
This is pre-specified and exploratory ancillary analysis to the ENSURE-AF trial, with 
consideration of the robust sample size; our observations are limited by the low event 
rates for the primary efficacy and safety endpoints. We also had shorter follow-up 
period compared to the Phase 3 NOAC trials, such that we were unable to fully 
assess the longer term impact on renal function of edoxaban compared to 
enoxaparin–warfarin. 
 
Conclusion 
In conclusion, given the small number of events in ENSURE-AF, no apparent effect 
of renal (dys)function was demonstrated on clinical outcomes when comparing 
edoxaban to enoxaparin–warfarin for cardioversion; the efficacy and safety of 
edoxaban remained consistent even in patients with normal or supranormal renal 
function. 
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Table 1 Clinical Demography of Patients in Relation to Renal Function Strata 
 
 (a) Edoxaban by CrCl 
 Total ≥15 and 
≤30 ml/min 
>30 and 
≤50 
ml/min 
>50 and 
<80 
ml/min 
≥80 
ml/min 
≥95 
ml/min 
N 1095 10 73 304 643 459 
Age, Mean (SD) 64.3 (10.34) 76.6 (10.54) 76.7 (8.26) 70.0 (7.52) 59.9 (9.03) 58.0 (8.89) 
Sex, n (%)       
   Male 721 (65.8) 4 (40.0) 38 (52.1) 157 (51.6) 484 (75.3) 358 (78.0) 
   Female 374 (34.2) 6 (60.0) 35 (47.9) 147 (48.4) 159 (24.7) 101 (22.0) 
Atrial Fibrillation 
History n (%) 
      
   Paroxysmal 208 (19.0) 2 (20.0) 18 (24.7) 60 (19.7) 111 (17.3) 82 (17.9) 
   Persistent 887 (81.0) 8 (80.0) 55 (75.3) 244 (80.3) 532 (82.7) 377 (82.1) 
Medical History, n (%)       
   Congestive heart  
       failure 
476 (43.5) 6 (60.0) 34 (46.6) 133 (43.8) 275 (42.8) 191 (41.6) 
   Coronary artery  
      disease 
181 (16.5) 3 (30.0) 24 (32.9) 57 (18.8) 88 (13.7) 64 (13.9) 
   Hypertension 850 (77.6) 8 (80.0) 60 (82.2) 241 (79.3) 485 (75.4) 337 (73.4) 
   Diabetes 218 (19.9) 2 (20.0) 20 (27.4) 63 (20.7) 118 (18.4) 91 (19.8) 
Ischemic/embolic  
   stroke or transient  
      ischemic attack 
68 (6.2) 2 (20.0) 11 (15.1) 29 (9.5) 23 (3.6) 16 (3.5) 
Life-Threatening Bleed 3 (0.3) 0 0 1 (0.3) 1 (0.2) 1 (0.2) 
CHA2DS2VASc,  
   Mean (SD) 
2.6 (1.49) 4.4 (1.26) 4.0 (1.53) 3.2 (1.45) 2.1 (1.25) 2.0 (1.20) 
HAS-BLED, Mean 
(SD) 
0.9 (0.78) 1.3 (0.82) 1.4 (0.67) 1.2 (0.71) 0.7 (0.73) 0.6 (0.74) 
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 (b) Warfarin by CrCl 
 Total ≥15 and 
≤30 ml/min 
>30 and 
≤50 
ml/min 
>50 and 
<80 ml/min 
≥80 
ml/min 
≥95 ml/min 
N 1104 8 68 315 636 444 
Age, Mean (SD) 64.2 (10.75) 79.5 (5.24) 75.7 (7.21) 70.4 (7.67) 59.6 (9.78) 57.2 (9.43) 
Sex, n (%)       
   Male 722 (65.4) 2 (25.0) 29 (42.6) 170 (54.0) 471 (74.1) 342 (77.0) 
   Female 382 (34.6) 6 (75.0) 39 (57.4) 145 (46.0) 165 (25.9) 102 (23.0) 
Atrial Fibrillation  
   History n (%) 
      
     Paroxysmal 207 (18.8) 2 (25.0) 18 (26.5) 64 (20.3) 105 (16.5) 74 (16.7) 
     Persistent 890 (80.6) 6 (75.0) 50 (73.5) 251 (79.7) 529 (83.2) 368 (82.9) 
Medical History, n (%)       
   Congestive heart  
      failure 
484 (43.8) 3 (37.5) 34 (50.0) 133 (42.2) 280 (44.0) 212 (47.7) 
   Coronary artery  
      disease 
197 (17.8) 2 (25.0) 18 (26.5) 62 (19.7) 99 (15.6) 67 (15.1) 
   Hypertension 864 (78.3) 6 (75.0) 56 (82.4) 260 (82.5) 477 (75.0) 325 (73.2) 
   Diabetes 197 (17.8) 1 (12.5) 12 (17.6) 49 (15.6) 116 (18.2) 74 (16.7) 
Ischemic/embolic  
   stroke or transient  
      ischemic attack 
66 (6.0) 1 (12.5) 5 (7.4) 25 (7.9) 29 (4.6) 25 (5.6) 
Life-Threatening Bleed 3 (0.3) 0 0 2 (0.6) 0 0 
CHA2DS2VASc,  
   Mean (SD) 
2.6 (1.40) 4.4 (0.92) 3.9 (1.38) 3.2 (1.29) 2.2 (1.25) 2.0 (1.24) 
HAS-BLED, Mean 
(SD) 
0.9 (0.79) 1.9 (0.64) 1.4 (0.76) 1.2 (0.68) 0.7 (0.75) 0.6 (0.72) 
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Table 2 Efficacy and Safety Endpoints in Relation to Renal Function Strata, and Treatment Allocation 
 
 
Total by Treatment 
No. of events / Total No. (%) 
  
Primary efficacy 
endpoint* 
ITT Analysis Set 
Overall Treatment 
Period 
Edoxaban 
N=1095 
Warfarin + 
Enoxaparin 
N=1104 OR (95% CI) 
Mean TiTR 
with 
warfarin/ 
enoxaparin 
arm 
CrCl, ml/min 
   ≥15 and ≤30 
   >30 and <50 
   ≥50 and <80 
   ≥80 
         ≥95 
 
0/10 (0.0) 
0/73 (0.0) 
2/304 (0.7) 
2/643 (0.3) 
0/459 (0.0) 
 
0/8 (0.0) 
2/68 (2.9) 
5/315 (1.6) 
3/636 (0.5) 
2/444 (0.5) 
 
- 
0.38 (0, 3.22) 
0.41 (0.04, 2.53) 
0.66 (0.05, 5.77) 
0.40 (0, 3.36) 
 
Primary safety 
endpoint† 
Safety Analysis Set 
On Treatment 
Period N=1067 N=1082   
CrCl, ml/min 
   ≥15 and ≤30 
   >30 and <50 
   ≥50 and <80 
   ≥80 
         ≥95 
 
0/10 (0) 
2/70 (2.9) 
6/297 (2.0) 
5/630 (0.8) 
4/451 (0.9) 
 
0/8 (0) 
1/67 (1.5) 
3/308 (1.0)  
6/631 (1.0) 
3/440 (0.7) 
 
- 
1.94 (0.10, 116.23) 
2.10 (0.44, 13.06) 
0.83 (0.20, 3.30) 
1.30 (0.22, 8.95) 
 
95.2 
66.8 
68.9 
71.8 
73.8 
Net clinical benefit‡ 
ITT Analysis Set 
Overall Treatment 
Period N=1095 N=1104   
CrCl, ml/min 
   ≥15 and ≤30 
 
0/10 (0) 
 
0/8 (0) 
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   >30 and <50 
   ≥50 and <80 
   ≥80 
         ≥95 
0/73 (0) 
3/304 (1.0) 
4/643 (0.6) 
2/459 (0.4) 
2/68 (2.9) 
7/315 (2.2) 
6/636 (0.9) 
3/444 (0.7) 
0.38 (0, 3.22) 
0.44 (0.07, 1.95) 
0.66 (0.14, 2.79) 
0.64 (0.05, 5.65) 
 
*Composite of stroke, systemic embolic events (SEEs), myocardial infarction (MI) and cardiovascular (CV) death occurring between 
randomization until the end of study.  
†Composite of major and clinically-relevant non-major bleeding, from the time of first administration of study drug to end of treatment +3 days. 
‡Composite of stroke, SEE, MI, CV mortality, and major bleedings occurring between randomization until the end of study. 
Median unbiased estimate is used for odds ratio. 
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Table 3: Summary of Renal Function (by eGFR); Safety Analysis Set 
 
 
Edoxaban 
N=1067 
Enoxaparin/ 
Warfarin 
N=1082 
Baseline   
   n 1007 1014 
   Mean, ml/min 94.1 94.3 
   SD 35.81 34.72 
   Median, ml/min 90.0 90.0 
   Minimum, ml/min 20 23 
   Maximum, ml/min 313 264 
   
End of Treatment   
   n 983 955 
   Mean, ml/min 94.9 96.4 
   SD 36.67 36.20 
   Median, ml/min 90 91 
   Minimum, ml/min 22 17 
   Maximum, ml/min 318 296 
   
Change from 
   Baseline 
  
   n 944 905 
   Mean* 0.9 1.7 
   SD 15.61 15.33 
   Median 0 1 
   Minimum -85 -89 
   Maximum 108 91 
   
Worsening n (%)   
   Yes 55 (5.83) 44 (4.86) 
   No† 889 (94.17) 861 (95.14) 
 
*P value 0.2159. 
†P value 0.3571. 
P-values for continuous variable and categorical variable are from ANOVA model with treatment 
as factor and Chi-square test, respectively. 
End of treatment: Day 28 assessment is used if it is available (last data if multiple Day 28 
assessments). Latest post-dose assessment is used if Day 28 is not available.  
Worsening is defined as a decrease of greater than 20% from baseline. 
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Figure Legends 
 
Figure 1. Efficacy Analysis Event Rate by CrCl at Baseline 
CrCl = creatinine clearance. 
Composite of stroke, systemic embolic events (SEEs), myocardial infarction (MI) and 
cardiovascular (CV) death occurring between randomization until the end of study. 
 
Figure 2. Safety Analysis Event Rate by CrCl at Baseline 
CrCl = creatinine clearance. 
Composite of major and clinically-relevant non-major bleeding, from the time of first 
administration of study drug to end of treatment +3 days. 
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Figure 1 
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Figure 2 
 
